For many young scientists, a PhD is the start of an international career.The next step is often predictable: a prestigious research grant, a postdoctoral position abroad, publications in leading journals, and eventually a faculty position.Dr. Parul Ganju had these opportunities.He had obtained a PhD in skin biology from the National Institute of Immunology (NII), New Delhi. He had a government research grant up his sleeve. A postdoctoral position in the United States was also on the table.But during his doctoral research, something happened that changed his definition of success.He began meeting people living with vitiligo, a chronic autoimmune disease in which the body’s immune system destroys pigment-producing cells, leaving white patches on the skin. In India, where appearance often influences confidence, relationships and even career opportunities, she realized that the disease affected much more than the skin.
Why Dr. Parul Ganju turned down an opportunity in the United States to pursue vitiligo treatment. (Photo: LinkedIn)
“The effect of this disease was enormous,” he would later recall. “People were hoping something would work.”That question stayed with her long after she finished her Ph.D.Instead of asking where her career would take her, she began to ask something else.Who was actually building a cure?
When patients changed the direction of a scientist’s career
Dr. Ganju had spent years studying the biology of the skin, but interacting with patients gave her research a new purpose.He realized that despite decades of scientific progress, treatment options for vitiligo were limited.Commonly prescribed medications, especially steroids, often suppress the body’s immune system broadly to slow the disease. Although they can help some patients, they do not permanently stop the disease, cannot restore lost pigmentation in many cases, and can cause significant side effects when used for long periods.For millions of people living with vitiligo, there was still no treatment that directly targeted the root cause of the disease.Instead of accepting this reality, he decided to work to change it.
He left a comfortable career to build a biotech startup
In 2016, Dr. Parul Ganju co-founded Ahammune Biosciences in Pune with her PhD collaborator, Dr. Krishnamurthy Natarajan, a professor at Jawaharlal Nehru University (JNU).It was an unconventional decision.Building a biotech company meant years of uncertainty, fundraising, failed experiments and long clinical trials.However, he believed that publishing another research paper would not immediately improve a patient’s life.The development of a drug could.The company’s lead drug candidate, AB1001, is designed to work differently from existing treatments.Instead of suppressing the body’s immune system in general, it aims to block the specific cell signaling pathway responsible for destroying melanocytes, the pigment-producing cells affected by vitiligo.Dr Ganju has described the approach simply as ‘cutting fuel to the fire’.Today, AB1001 has successfully completed Phase 1 clinical trials and advanced to Phase 2, bringing it one step closer to potentially becoming a new treatment option.The company has also secured patents in several countries and has raised around US$8 million from investors including pi Ventures, Ideaspring Capital and Kotak Alternate Assets.
Why their story matters World Allergy Day
Today, July 8, is observed worldwide as World Allergy Daya reminder of the growing impact of immune-related disorders and the importance of advancing research into immune-driven conditions.Although vitiligo is not classified as an allergy, it is an autoimmune disease, where the immune system mistakenly attacks healthy cells in the body.The observance provides an opportunity to appreciate scientists working to better understand immune disorders and develop targeted therapies that improve patients’ lives.It also aligns with a wider message celebrated through initiatives such as this one National Love Your Skin Day — This healthy skin is much more than appearance. It’s about trust, well-being and quality of life.
Sometimes the most important career decision is not where you go, but why you stay
For students, Dr. Parul Ganju’s journey offers a different way of thinking about success.Many graduates dream of research positions abroad, prestigious scholarships and international careers.There is nothing wrong with such ambitions.But his story shows that sometimes the biggest impact comes from choosing a harder path, one driven by purpose rather than prestige.Millions of people worldwide continue to live with vitiligo, and India has one of the largest patient populations.Whether AB1001 becomes a widely available treatment will depend on the outcome of ongoing clinical trials and regulatory approvals.But one thing is already clear.A scientist who could have spent her career publishing papers chose to spend it solving a problem that patients had been living with for decades.And sometimes, this is the kind of research that changes lives.Exemption from liability: This article is based on publicly available information about Dr Parul Ganju, Ahmmune Biosciences and the company’s ongoing clinical research. References to AB1001 refer to its current stage of clinical development. The drug remains under investigation and has not yet received regulatory approval for general clinical use. The article is for informational and educational purposes only and should not be considered medical advice.